Paper Details

  1. Home
  2. Paper Details

Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease.

Author: BrownC D, McCroryD C

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Ipratropium bromide was not more effective than short-acting beta2-agonists in treating acute exacerbations of COPD. The combination of ipratropium bromide and a beta2-agonist did not increase the effect on FEV1 more than either used alone.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Inhaled bronchodilators form the mainstay of treatment for acute exacerbations of COPD. Two types of agent are used routinely, either singly or in combination: anticholinergic agents and beta2-sympathomimetic agonists. OBJECTIVES: To assess the effect of anti-cholinergic agents on lung ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753782/

データ提供：米国国立医学図書館（NLM）

Anti-cholinergic Bronchodilators vs. Beta2-Sympathomimetic Agents for COPD: A Comparative Study

The [COPD], a chronic lung disease, can be a real lungful of challenges, often leading to exacerbations that leave patients struggling for breath. This study delves into the treatment options for COPD exacerbations, comparing the effectiveness of two types of bronchodilators: anti-cholinergics and beta2-sympathomimetics. The researchers found that both types of bronchodilators were effective in improving lung function, with no significant difference in their effectiveness. This is like having two different pathways through the desert, both leading to a refreshing oasis.

Treating COPD Exacerbations: A Choice of Pathways

This study provides valuable insights into the treatment options for COPD exacerbations, suggesting that both anti-cholinergic and beta2-sympathomimetic bronchodilators can be effective. This is like having a variety of tools to navigate the desert, each with its own advantages and disadvantages.

Managing COPD: A Team Effort

This research emphasizes the importance of a collaborative approach to managing COPD. It's like a caravan traversing the desert - a team of healthcare professionals working together to ensure the best possible outcome for patients.

Dr. Camel's Conclusion

This study provides valuable information for treating COPD exacerbations, suggesting that both anti-cholinergic and beta2-sympathomimetic bronchodilators can be effective. It highlights the importance of a collaborative approach to managing this challenging condition.

Date :
  1. Date Completed 2003-02-21
  2. Date Revised 2022-01-13
Further Info :

Pubmed ID

12519615

DOI: Digital Object Identifier

PMC8753782

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.